Skip to main content

Table 1 General characteristics of study participants (adjusted)

From: Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study

Characteristic   Total HBsAg(+) HBsAb(+) HBeAg(+) HBeAb(+) HBcAb(+) Anti-HCV
  Population %(95%CI) %(95%CI) %(95%CI) %(95%CI) %(95%CI) %(95%CI)
Total number Adjusted rate 6541 3.8(3.33, 4.26) 55.2(54.0, 56.4) 0.72(0.52, 0.92) 14.9(14.0.6, 15.8) 60.9(59.7, 62.1) 0.36(0.21, 0.50)
Gender
  Male 3281 4.58(3.86, 5.30) 55.4(53.7, 57.1) 0.92(0.59, 1.25) 14.9(13.68, 16.12) 59.8(58.1, 61.5) 0.43(0.12, 0.65)
Female 3260 3.0(2.41, 3.59) 54.9(53.2, 56.6) 0.51(0.27, 0.75) 14.8(13.62, 16.06) 61.9(60.3, 63.6) 0.33(0.13, 0.53)
Age (years)
  < 1 382 0.0(0, 0) 84.8(81.2, 88.4) 0.0(0, 0) 8.9(6.0, 11.8) 75.1(70.8, 79.4) 0(0,0)
1–4 1614 0.2(0, 0.42) 60.7(58.3, 63.1) 0.1(0, 0.25) 8.6(7.2, 10.0) 71.7(69.5, 73.9) 0.3(0.03, 0.57)
5–14 1413 0.2(0, 0.43) 53.0(50.4, 55.6) 0.1(0, 0.26) 6.3(5.0, 7.6) 60.7(58.2, 63.2) 0.1(0, 0.26)
15–29 1808 2.9(2.1, 3.7) 62.9(60.7, 65.1) 0.7(0.32, 1.10) 12.3(10.8, 13.8) 57.5 (55.2, 59.8) 0.4(0.1, 0.7)
30–39 502 4.4(2.6,6.2) 53.6(49.2,58.0) 1.2 (0.25, 2.2) 14.5(11.4,17.6) 59.6(55.3,63.9) 0(0,0)
40–49 455 5.9(3.73,8.07) 49.5(44.9,54.1) 0.9(0.03,1.77) 17.4(13.9,20.9) 62.9(58.5,67.3) 0.2(0,0.61)
50–59 367 4.9(2.7,7.1) 49.0(43.9,54.1) 0.5(0,1.2) 23.4(19.1,27.7) 63.2(58.3,68.1) 1.1(0.03, 2.2)
HBV vaccination
  Yes 4289 37(0.9) 2681(62.5) 13(0.3) 361(8.4) 2846(66.4) 9(0.2)
No 961 42(4.4) 468(48.7) 7(0.7) 169(17.6) 544(56.6) 2(0.2)
Unclear 1291 48(3.7) 714(55.3) 8(0.6) 191(14.8) 768(59.5) 9(0.7)